TY - JOUR
T1 - State of the translational science
T2 - Summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003
AU - Zelent, Arthur
AU - Waxman, Samuel
AU - Carducci, Michael
AU - Wright, John
AU - Zweibel, James
AU - Gore, Steven D.
PY - 2004/7/15
Y1 - 2004/7/15
N2 - A workshop was held in Baltimore, Maryland in January 2003 to discuss translational aspects of cancer therapies targeted at impacting aberrant gene transcription due to epigenetic changes. The mission of the meeting was the development of strategies for scientifically sound, clinically feasible applications targeting epigenetics in cancer therapy. Sessions included preclinical discussions of DNA methylation, the histone code, chromatin remodeling, and transcriptional control. Data on the histone deacetylase and DNA methyltransferase inhibitors under preclinical and clinical investigation were presented and discussed. The optimal correlative laboratory studies for monitoring clinical trials with these agents remain controversial. DNA methyltransferase and histone deacetylase inhibitors will be combined with each other to maximally re-express genes silenced through promoter methylation. Other classes of agents that may be rationally combined with these classes of drugs include retinoids, steroid hormones, and cytotoxic drugs.
AB - A workshop was held in Baltimore, Maryland in January 2003 to discuss translational aspects of cancer therapies targeted at impacting aberrant gene transcription due to epigenetic changes. The mission of the meeting was the development of strategies for scientifically sound, clinically feasible applications targeting epigenetics in cancer therapy. Sessions included preclinical discussions of DNA methylation, the histone code, chromatin remodeling, and transcriptional control. Data on the histone deacetylase and DNA methyltransferase inhibitors under preclinical and clinical investigation were presented and discussed. The optimal correlative laboratory studies for monitoring clinical trials with these agents remain controversial. DNA methyltransferase and histone deacetylase inhibitors will be combined with each other to maximally re-express genes silenced through promoter methylation. Other classes of agents that may be rationally combined with these classes of drugs include retinoids, steroid hormones, and cytotoxic drugs.
UR - http://www.scopus.com/inward/record.url?scp=3242722145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242722145&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-1219-03
DO - 10.1158/1078-0432.CCR-1219-03
M3 - Article
C2 - 15269133
AN - SCOPUS:3242722145
SN - 1078-0432
VL - 10
SP - 4622
EP - 4629
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 14
ER -